Terms: = Endocrine gland cancer AND ER, estrogen receptor AND Staging
22 results:
1. Clinicopathological pattern of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 over-expression of epithelial ovarian carcinomas in Nigeria.
Ajani MA; Lawan A; Oke T; Khramtsova G; Nwanji I; Salami A; Awolude O; Ebili H; Onwukamuche ME; Sveen E; Yoshimatsu T; Olopade OI
Afr Health Sci; 2023 Sep; 23(3):236-244. PubMed ID: 38357171
[TBL] [Abstract] [Full Text] [Related]
2. [WHO Histological Classification of Pituitary Tumors].
Nishioka H
No Shinkei Geka; 2023 Jul; 51(4):642-653. PubMed ID: 37491061
[TBL] [Abstract] [Full Text] [Related]
3. Ovarian Mesonephric-Like Adenocarcinoma With Recurrent Liver Metastases: A Case Report with Analysis of Therapeutic Molecular Targets.
Sugitani A; Ogawa A; Yoshida H; Kobayashi-Kato M; Kikkawa N; Tanase Y; Uno M; Ishikawa M; Kato T
Int J Surg Pathol; 2024 May; 32(3):578-585. PubMed ID: 37345348
[TBL] [Abstract] [Full Text] [Related]
4. Response to Surgery Assessments for Sparing Radioiodine Remnant Ablation in Intermediate-Risk Papillary Thyroid cancer.
Zhang X; Liu JR; Mu ZZ; Cheng XQ; Lin YS
J Clin Endocrinol Metab; 2023 May; 108(6):1330-1337. PubMed ID: 36567646
[TBL] [Abstract] [Full Text] [Related]
5. A novel online calculator to predict early recurrence and long-term survival of patients with resectable pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: A multicenter study.
Zhang XP; Gao YX; Xu S; Zhao GD; Hu MG; Tan XL; Zhao ZM; Liu R
Int J Surg; 2022 Oct; 106():106891. PubMed ID: 36165934
[TBL] [Abstract] [Full Text] [Related]
6. HER2-positive pure mucinous breast carcinoma: A case report and literature review.
Zhao X; Yang X; Gao R; Zhai L; Yang L; Yu K
Medicine (Baltimore); 2020 Aug; 99(33):e20996. PubMed ID: 32871976
[TBL] [Abstract] [Full Text] [Related]
7. [Expression of ARID1A in ovarian seromucinous neoplasms and its clinicopathological significance].
Ding XH; Tian X; Wang LQ; Wang Y; Liu AJ
Zhonghua Bing Li Xue Za Zhi; 2020 Jun; 49(6):588-593. PubMed ID: 32486536
[No Abstract] [Full Text] [Related]
8. 30mCi radioactive iodine achieving comparative excellent response in intermediate/high-risk nonmetastatic papillary thyroid cancer: a propensity score matching study.
Zhang Y; Wang C; Zhang X; Li H; Li X; Lin Y
Endocrine; 2018 Dec; 62(3):655-662. PubMed ID: 30145748
[TBL] [Abstract] [Full Text] [Related]
9. PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma.
Chapel DB; Husain AN; Krausz T; McGregor SM
Am J Surg Pathol; 2017 Dec; 41(12):1675-1682. PubMed ID: 28877056
[TBL] [Abstract] [Full Text] [Related]
10. Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor α in high-grade serous ovarian carcinoma.
Taube ET; Denkert C; Sehouli J; Unger U; Kunze CA; Budczies J; Dietel M; Braicu E; Darb-Esfahani S
Hum Pathol; 2017 Sep; 67():30-36. PubMed ID: 28414091
[TBL] [Abstract] [Full Text] [Related]
11. Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC).
Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
J Ovarian Res; 2017 Jan; 10(1):7. PubMed ID: 28122595
[TBL] [Abstract] [Full Text] [Related]
12. In Patients With Low- to Intermediate-Risk Thyroid cancer, a Preablative Thyrotropin Level of 30 μIU/mL Is Not Adequate to Achieve Better Response to 131I Therapy.
Zhao T; Liang J; Guo Z; Li T; Lin Y
Clin Nucl Med; 2016 Jun; 41(6):454-8. PubMed ID: 26914559
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
[TBL] [Abstract] [Full Text] [Related]
14. ER-alpha and ER-beta expression in differentiated thyroid cancer: relation with tumor phenotype across the TNM staging and peri-tumor inflammation.
Magri F; Capelli V; Gaiti M; Villani L; Zerbini F; La Manna L; Rotondi M; Chiovato L
Endocrine; 2015 Jun; 49(2):429-35. PubMed ID: 25338203
[TBL] [Abstract] [Full Text] [Related]
15. Emerging molecular markers for the prognosis of differentiated thyroid cancer patients.
Baldini E; Sorrenti S; Tuccilli C; Prinzi N; Coccaro C; Catania A; Filippini A; Bononi M; De Antoni E; D'Armiento M; Ulisse S
Int J Surg; 2014; 12 Suppl 1():S52-6. PubMed ID: 24862669
[TBL] [Abstract] [Full Text] [Related]
16. Immunohistochemical expression of ERα, ERβ, and TFF1 in type I and II ovarian tumors.
Abdou AG; Aiad HA; Asaad NY; Abd El-Wahed MM; Serag El-Dien M
Appl Immunohistochem Mol Morphol; 2014 Jul; 22(6):421-32. PubMed ID: 24162262
[TBL] [Abstract] [Full Text] [Related]
17. An immunohistochemical panel to distinguish ovarian from uterine serous papillary carcinomas.
Zhang Y; Garcia-Buitrago MT; Koru-Sengul T; Schuman S; Ganjei-Azar P
Int J Gynecol Pathol; 2013 Sep; 32(5):476-81. PubMed ID: 23896709
[TBL] [Abstract] [Full Text] [Related]
18. Primary peritoneal serous papillary carcinoma: a clinical and pathological study.
Liu Q; Lin JX; Shi QL; Wu B; Ma HH; Sun GQ
Pathol Oncol Res; 2011 Sep; 17(3):713-9. PubMed ID: 21647781
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovary.
Burges A; Brüning A; Dannenmann C; Blankenstein T; Jeschke U; Shabani N; Friese K; Mylonas I
Arch Gynecol Obstet; 2010 Mar; 281(3):511-7. PubMed ID: 19639330
[TBL] [Abstract] [Full Text] [Related]
20. Ovarian clear cell carcinoma with papillary features: a potential mimic of serous tumor of low malignant potential.
Sangoi AR; Soslow RA; Teng NN; Longacre TA
Am J Surg Pathol; 2008 Feb; 32(2):269-74. PubMed ID: 18223330
[TBL] [Abstract] [Full Text] [Related]
[Next]
